摘要:Xeris制药公司宣布美国FDA首次批准使用室温下稳定的高血糖素注射液治疗>2岁糖尿病患者的严重低血糖症。批准是根据3次Ⅲ期临床试验的阳性结果,该药与普通高血糖素急救针比较,治疗1型糖尿病严重低血糖症的疗效、安全性和实用性。儿童剂量为0.5 mg/0.1 ml,青年或成人剂量为1 mg/0.2 ml,由预装注射液的自动注射针完成给药。结果成功率为99%~100%。最常见副作用是恶心、呕吐和低血糖。
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering